Posts by: Patricia Inacio, PhD

News

ProMIS Neurosciences announced plans to initiate the development of its lead antibody candidate, PMN310, as a potential treatment for Alzheimer’s disease. The investigational therapy is expected to enter clinical Phase 1 trials in 2019. ... Read more

June 6, 2018June 6, 2018

Type 2 Diabetes Therapies May Help Relieve Alzheimer’s Symptoms, Researchers Say

News

Medications for type 2 diabetes may help treat symptoms of Alzheimer’s, as these two conditions share common disease mechanisms, according to recent research. Fernanda De Felice, PhD, an associate ... Read more

June 1, 2018June 1, 2018

Phase 1 Trial Assessing Stem Cell Therapy Recruiting Alzheimer’s Patients in Florida

News

A Phase 1 trial to evaluate the safety and effectiveness of Longeveron’s allogeneic mesenchymal stem cells (LMSCs) in patients with Alzheimer’s disease is currently looking for participants, the biopharmaceutical ... Read more

May 18, 2018May 18, 2018

Phase 2 Trial Testing Alkahest’s Investigational GRF6019 for Alzheimer’s Doses First Patient

News

Alkahest‘s Phase 2 clinical trial testing GRF6019 — an experimental blood-derived protein — in patients with mild to moderate Alzheimer’s disease has dosed its first participant, the company recently announced. ... Read more

May 11, 2018May 11, 2018

Phase 3 of Large-scale Alzheimer’s Disease Study Looking to Enroll Hundreds of Participants

News

The Alzheimer’s Disease Neuroimaging Initiative (ADNI) is searching for participants to enroll in one of the largest and longest trials on Alzheimer’s disease. This ongoing study aims to develop ... Read more

April 30, 2018April 30, 2018

First Stem Cell Therapy for Alzheimer’s Disease Approved, Applied in Japan

News

A stem cell therapy developed by the biotech company Nature Cell and the Biostar Stem Cell Research Institute, both based in South Korea, has been formally approved in Japan and is now available ... Read more

April 25, 2018April 25, 2018

Blood Test for Toxic Amyloid May Detect Alzheimer’s 8 Years Before Symptoms, Study Says

News

A simple test of amyloid-beta protein levels in a person’s blood may offer a way to diagnose Alzheimer’s disease up to eight years before any clinical symptoms are evident, ... Read more

April 16, 2018April 17, 2018

#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients

News

An injection of IONIS-MAPTRx resulted in a 70 percent decrease in tau protein produced in the brains of non-human primates, researchers at Ionis Pharmaceuticals, the potential treatment’s maker, are ... Read more

April 13, 2018April 13, 2018

Chronic Exposure to Caffeine Worsened Symptoms in Alzheimer’s Mouse Model

News

Long-term exposure to caffeine worsens Alzheimer’s disease symptoms, a new mouse study shows. The study “Long-term Treatment with Low-Dose Caffeine Worsens BPSD-Like Profile in 3xTg-AD Mice Model of Alzheimer’s ... Read more

April 9, 2018April 9, 2018

Spanish Regulators Approve Phase 2 Trial of Oryzon’s Alzheimer’s Therapy

News

Spanish regulators have signed off on Oryzon Genomics’ plan to conduct a Phase 2 clinical trial of its Alzheimer’s therapy ORY-2001. The ETHERAL trial, which will cover patients with mild to moderate ... Read more

Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

ProMIS Working to Move Antibody Treatment for Alzheimer’s into Clinical Trials

Type 2 Diabetes Therapies May Help Relieve Alzheimer’s Symptoms, Researchers Say

Phase 1 Trial Assessing Stem Cell Therapy Recruiting Alzheimer’s Patients in Florida

Phase 2 Trial Testing Alkahest’s Investigational GRF6019 for Alzheimer’s Doses First Patient

Phase 3 of Large-scale Alzheimer’s Disease Study Looking to Enroll Hundreds of Participants

First Stem Cell Therapy for Alzheimer’s Disease Approved, Applied in Japan

Blood Test for Toxic Amyloid May Detect Alzheimer’s 8 Years Before Symptoms, Study Says

#AAN2018 – Early Data Supports Clinical Trial Now Testing IONIS-MAPTRx in Alzheimer’s Patients

Chronic Exposure to Caffeine Worsened Symptoms in Alzheimer’s Mouse Model

Spanish Regulators Approve Phase 2 Trial of Oryzon’s Alzheimer’s Therapy

Pin It on Pinterest